68Ga-NOTA-RM26 PET/CT in Glioma Patients

Trial ID: NCT06412952

Interventional - Phase 1 - Unknown status

The aim of this study was to investigate the value of 68Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor (GRPR) PET tracer, in the diagnosis of high WHO grade glioma and prediction the grade of glioma using positron-emission tomography/computed tomography (PET/CT).

Conditions

• Glioma

Interventions

• 68Ga-RM26

Eligibility

Inclusion criteria

• suspected or confirmed untreated glioma patients
• signed written consent.

Exclusion criteria

• pregnancy
• breastfeeding
• known allergy against Pentixafor
• any medical condition that in the opinion of the investigator,may
• significantly interfere with study compliance

Sponsor

Peking Union Medical College Hospital

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows